Literature DB >> 30705703

Low molecular weight heparin: the answer to adverse outcomes in obstetrics?

Ian Greer1.   

Abstract

Entities:  

Year:  2012        PMID： 30705703      PMCID： PMC6341510          DOI： 10.1258/om.2012.12e007

Source DB:  PubMed          Journal:  Obstet Med        ISSN： 1753-495X


× No keyword cloud information.
  4 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.

Authors:  Ida Martinelli; Piero Ruggenenti; Irene Cetin; Giorgio Pardi; Annalisa Perna; Patrizia Vergani; Barbara Acaia; Fabio Facchinetti; Giovanni Battista La Sala; Maddalena Bozzo; Stefania Rampello; Luca Marozio; Olimpia Diadei; Giulia Gherardi; Sergio Carminati; Giuseppe Remuzzi; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

3.  Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT.

Authors:  Johanna I P de Vries; M G van Pampus; W M Hague; P D Bezemer; J H Joosten
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

Review 4.  Thrombophilia in pregnancy: a systematic review.

Authors:  L Robertson; O Wu; P Langhorne; S Twaddle; P Clark; G D O Lowe; I D Walker; M Greaves; I Brenkel; L Regan; I A Greer
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.